Not a Replacement for Medical Treatment: BPC-157 is not intended to diagnose, treat, cure, or prevent any disease
However, such treatment should only be initiated by specialists with expertise in both bariatric surgery and obesity pharmacotherapy
Most BPC-157 preclinical work uses dosages around 10 mcg/kg administered intraperitoneally or subcutaneously in rodents, with study durations ranging from single administration to 14-day periods
The most common side effects were gastrointestinal, with the majority being mild to moderate in severity
If you're a tested athlete, you should also be aware that anti-doping rules can apply: USADA notes BPC-157 is prohibited under WADA's Prohibited List as an "unapproved substance"
Monday: Insurers can help improve care after adverse pregnancy outcomes